Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:6.4.1.2 (
acetyl-CoA carboxylase
)
2,876
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The present study documents the steady-state levels for the mRNAs encoding
acetyl-CoA carboxylase
(
ACC
), fatty acid synthase (FAS), stearoyl-CoA desaturase (SCD2) and brain long-chain acyl-CoA synthetase (BLACS) during mouse brain development. It is shown that
ACC
and FAS mRNA levels are at a maximum 5 days after birth, a time when cell proliferation is intense in the mouse brain, and then decrease steadily to reach 20% of those maximal values at day 20. The
ACC
transcript isoforms, which were detected in the central nervous system (CNS), originated from promoter P2 of the
ACC
gene. They encode
ACC
enzymes which cannot be phosphorylated at the Ser-1200 locus, thus indicating that brain
ACC
is highly sensitive to citrate activation. The developmental pattern for the SCD2 mRNA level is different from that of true myelin genes, such as
CGT
. Indeed, the steady-state levels for SCD2 and
CGT
in 5-day-old brain represent 85% and 5% of their maximal values, respectively. BLACS expression rose during the developmental period studied, but a slow decrease in the mRNA levels was not observed after postnatal day 20, unlike in "myelin-specific' genes. Therefore, it appears that the expression of the genes involved in fatty acid biosynthesis is independent of the myelinating signal in the mouse CNS.
...
PMID:Acetyl-CoA carboxylase gene expression in the developing mouse brain. Comparison with other genes involved in lipid biosynthesis. 905 Dec 61